Acasti pharma announces initiation of pharmacokinetic bridging study for gtx-104, the company's lead drug candidate for the treatment of subarachnoid hemorrhage

Study expected to be completed in the first half of 2022, with the goal to commence the phase 3 safety study in the second half of 2022 study expected to be completed in the first half of 2022, with the goal to commence the phase 3 safety study in the second half of 2022
ACST Ratings Summary
ACST Quant Ranking